xanthine has been researched along with Diabetes Mellitus, Type 2 in 9 studies
7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.
9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In total, 458 patients with type 2 diabetes not receiving antihyperuricemic agents were enrolled and their clinical parameters including plasma XOR activity and the cardio-ankle vascular index (CAVI) were measured." | 5.72 | Association of Plasma Xanthine Oxidoreductase with Arterial Stiffness in Type 2 Diabetes with Liver Dysfunction. ( Ban, N; Ishihara, N; Murano, T; Murase, T; Nakamura, S; Nakamura, T; Ohira, M; Oka, R; Saiki, A; Tanaka, S; Tatsuno, I; Watanabe, Y; Yamaguchi, T, 2022) |
| "Linagliptin is a new oral antidiabetic agent associated with minimal risk of hypoglycemia, which holds promise for treatment of type 2 diabetes." | 2.46 | Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. ( Deacon, CF; Holst, JJ, 2010) |
| "In total, 458 patients with type 2 diabetes not receiving antihyperuricemic agents were enrolled and their clinical parameters including plasma XOR activity and the cardio-ankle vascular index (CAVI) were measured." | 1.72 | Association of Plasma Xanthine Oxidoreductase with Arterial Stiffness in Type 2 Diabetes with Liver Dysfunction. ( Ban, N; Ishihara, N; Murano, T; Murase, T; Nakamura, S; Nakamura, T; Ohira, M; Oka, R; Saiki, A; Tanaka, S; Tatsuno, I; Watanabe, Y; Yamaguchi, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Ohira, M | 1 |
| Tanaka, S | 1 |
| Watanabe, Y | 1 |
| Nakamura, S | 1 |
| Oka, R | 1 |
| Yamaguchi, T | 1 |
| Ban, N | 1 |
| Saiki, A | 1 |
| Ishihara, N | 1 |
| Murano, T | 1 |
| Murase, T | 2 |
| Nakamura, T | 2 |
| Tatsuno, I | 1 |
| Svistounov, D | 1 |
| Solbu, MD | 1 |
| Jenssen, TG | 1 |
| Mathisen, UD | 1 |
| Hansen, T | 1 |
| Elgstøen, KBP | 1 |
| Zykova, SN | 1 |
| Chen, L | 1 |
| Li, H | 1 |
| Ru, Y | 1 |
| Song, Y | 1 |
| Shen, Y | 1 |
| Zhao, L | 1 |
| Huang, G | 1 |
| Chen, Y | 1 |
| Qi, Z | 1 |
| Li, R | 1 |
| Dong, C | 1 |
| Fang, J | 1 |
| Lam, TK | 1 |
| Yang, Z | 1 |
| Cai, Z | 2 |
| Okuyama, T | 1 |
| Shirakawa, J | 1 |
| Miyashita, D | 1 |
| Inoue, R | 1 |
| Kyohara, M | 1 |
| Togashi, Y | 1 |
| Terauchi, Y | 1 |
| Li, Q | 1 |
| Meng, L | 1 |
| Zhou, S | 1 |
| Deng, X | 1 |
| Wang, N | 1 |
| Ji, Y | 1 |
| Peng, Y | 1 |
| Xing, J | 1 |
| Yao, G | 1 |
| Xia, JF | 1 |
| Liang, QL | 1 |
| Hu, P | 1 |
| Wang, YM | 1 |
| Li, P | 1 |
| Luo, GA | 1 |
| Deacon, CF | 1 |
| Holst, JJ | 1 |
| Lin, K | 1 |
| Wang, F | 1 |
| Zhang, W | 1 |
| Zhou, W | 1 |
| Shibutani, Y | 1 |
| Ueo, T | 1 |
| Yamamoto, T | 1 |
| Takahashi, S | 1 |
| Moriwaki, Y | 1 |
| Higashino, K | 1 |
1 review available for xanthine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2010 |
1 trial available for xanthine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Body Mass Index; Diabetes Melli | 2021 |
7 other studies available for xanthine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Association of Plasma Xanthine Oxidoreductase with Arterial Stiffness in Type 2 Diabetes with Liver Dysfunction.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Liver Diseases; Vascular Stiffness; Xanthine; Xa | 2022 |
Development of quantitative assay for simultaneous measurement of purine metabolites and creatinine in biobanked urine by liquid chromatography-tandem mass spectrometry.
Topics: Allantoin; Chromatography, High Pressure Liquid; Chromatography, Liquid; Creatinine; Diabetes Mellit | 2022 |
Xanthine-derived reactive oxygen species exacerbates adipose tissue disorders in male db/db mice induced by real-ambient PM2.5 exposure.
Topics: Adipose Tissue; Adipose Tissue, Brown; Animals; Diabetes Mellitus, Type 2; Energy Metabolism; Male; | 2023 |
Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study.
Topics: Animals; Benzoic Acid; Cell Survival; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mel | 2019 |
Correlations of six related purine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients.
Topics: Adenosine; Aged; Asian People; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic | 2009 |
Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4.
Topics: Binding Sites; Catalytic Domain; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Pepti | 2013 |
A case of classical xanthinuria (type 1) with diabetes mellitus and Hashimoto's thyroiditis.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Middle Aged; Thyroiditis, Autoimmune; Xanthine | 1999 |